Clinical Trial Update: Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer [Phase 1]

View source ↗

Summary

A Phase 1 imaging trial using the CCR2-targeting radiotracer 64Cu-DOTA-ECL1i in head and neck cancer was terminated, with results posted on 2024-02-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• 64Cu-DOTA-ECL1i (64Cu-DOTA-ECL1i)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Head and Neck Cancer | Phase 1 | Status: TERMINATED | Results posted: 2024-02-28